Precirix

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals.

[Precirix @precirix]

Precirix’ pioneering research with its single-domain antibody radiotheranostic targeting FAPα has been published in the December edition of the Journal of Nuclear Medicine!
Find out more here https://t.co/vXqFOiQzwB

#jnm #radiopharmaceuticals #nuclearmedicine

[Jeito @Jeito_life]

.@Precirix, our portfolio company developing novel targeted radiopharmaceuticals in oncology, won the award of Series B Finance Raise of the Year 2022 at the European #LifestarsAwards 👏 Last Match, Jeito participated in this €80M financing round to develop Precirix’s pipeline.

[flanders.bio @flandersbio]

Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225

https://t.co/OYWwEAhOlu

[Precirix @precirix]

We’re proud to announce our collaboration with Eckert & Ziegler for the supply of Actinium-225. This gives Precirix priority access to high-purity, non-carrier-added Actinium-225.

https://t.co/xwR1l8QhYh

[Natacha Sweert @_NatachaSweert_]

We are @SNM_MI and I cannot be more proud of our company & team! 💙 @precirix #SNMMI2022 #Vancouver #oncology #radiopharmaceuticals

[Natacha Sweert @_NatachaSweert_]

We are ready for @SNM_MI annual meeting in Vancouver! Please visit our booth 23! We have so much insights to share on our clinical and pre-clinical programs and maybe even some Belgian Chocolates! #SNMMI22 #PrecisionMedicine #oncology #clinicaltrials #Vancouver

[Precirix @precirix]

Precirix is attending #ASCO2022, reach out to learn more about our clinical research with precision radiopharmaceuticals
@_NatachaSweert_

[Natacha Sweert @_NatachaSweert_]

Working at our beautiful booth @flandersbio @precirix #kfg2022 #radiopharmaceuticals #clinicalresearch #oncology